Skip to main content
. 2022 Apr 18;14(8):2033. doi: 10.3390/cancers14082033

Figure 1.

Figure 1

The trend of mean lymphocyte counts of patients with locally advanced esophageal squamous cell carcinoma, either Groupphoton or Groupproton, from the baseline through the neoadjuvant chemoradiotherapy, and until before the planned esophagectomy.